Eluent for separating hemoglobin and method for separating same
The use of kosmotropic salts in the eluent, particularly carboxylic and hydroxycarboxylic acids, addresses the challenge of separating hemoglobin A0 from abnormal hemoglobins by improving the stability of water interactions and elution conditions, resulting in enhanced separation efficiency and reproducibility in cation exchange chromatography.
Patent Information
- Application Number
- PCT/JP2023/019317
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for separating hemoglobin A0 from abnormal hemoglobins E, D, S, and C using cation exchange chromatography face challenges in achieving efficient and reproducible separation, particularly due to similar ionic properties, which complicates the analysis of hemoglobin A2 and other components like fetal hemoglobin F and hemoglobin A1c, especially in short-time measurements.
The use of an eluent containing kosmotropic salts, such as carboxylic acids and hydroxycarboxylic acids like citric acid, which exhibit properties opposite to chaotropic salts in the Hofmeister series, improves the separation of hemoglobin components eluted after hemoglobin A0 by enhancing the stability of water-water interactions and optimizing elution conditions.
This approach allows for improved separation and analysis of hemoglobin A0 and abnormal hemoglobins E, D, S, and C, enhancing the reproducibility and efficiency of hemoglobin separation in cation exchange chromatography, even in short-time measurements, by effectively controlling elution power and peak resolution.
Smart Images

Figure JP2023019317_28112024_PF_FP_ABST
Abstract
Description
Eluent for separating hemoglobin and method for its separation
[0001] The present invention relates to an eluent for separating hemoglobin A2 or abnormal hemoglobins E, D, S, and C from hemoglobin A0, and a separation method thereof.
[0002] Analysis of hemoglobin in blood is an important diagnostic item. For example, hemoglobin A1c, which is glycated hemoglobin in blood, is a diabetes marker and various quantification methods have been used. Among these, cation exchange chromatography, which exhibits high measurement reproducibility even in short-term measurements, is widely used in the diagnostic field. Cation exchange chromatography can be used not only for hemoglobin A1c analysis but also for diagnosing hemoglobin disorders (hemoglobinopathies and thalassemias), and therefore, the development of related technologies has been actively promoted.
[0003] In the diagnosis of hemoglobin disorders using cation exchange chromatography, abnormal hemoglobins E, D, S, and C components, as well as hemoglobin A2, which is important for diagnosing thalassemia, are separated and quantified from hemoglobin A0. Even when measuring only hemoglobin A1c levels, it is desirable to be able to separate and detect abnormal hemoglobins because they affect the hemoglobin A1c level. However, separating these hemoglobin fractions quickly and reproducibly is difficult. In particular, hemoglobin A2, the abnormal hemoglobins E, D, S, and C, and hemoglobin A0 have very similar ionic properties and therefore interact very similarly with the packing material used in cation exchange chromatography, necessitating precise control of the chromatographic elution conditions. Rapid simultaneous analysis of these components with fetal hemoglobin F and hemoglobin A1c, which are components eluted before hemoglobin A0, is required, making an efficient hemoglobin separation and analysis method essential.
[0004] In contrast, additives added to the eluent in hemoglobin analysis have been shown to improve separation performance. Specifically, the effectiveness of strong chaotropic salts in the Hofmeister series, such as perchloric acid, has been demonstrated in the analysis of A1c, a component eluted before hemoglobin A0 (Patent Document 1). However, controlling the elution strength is difficult in the separation of hemoglobin A0 and subsequent components, and new methods have been explored, focusing on salt species with different properties outside the Hofmeister series. For example, ion-pair reagents have been found to be effective salt species for separating components after hemoglobin A0 (Patent Document 2). However, this method requires precise control of the pH of the eluent according to the isoelectric point (around pH 7.0) of each hemoglobin to be separated, making simultaneous analysis of multiple hemoglobins eluted before hemoglobin A0 not necessarily easy.
[0005] Meanwhile, a method for efficiently separating components eluted after hemoglobin A0 by utilizing a large pH gradient in the eluent used has been reported (Patent Document 3). Specifically, a method for separating hemoglobin A0 and A2 has been reported in which an eluent A used to elute hemoglobin components eluted before hemoglobin A0 and an eluent B used to elute hemoglobin components eluted after hemoglobin A0, the eluent B having a pH 0.5 or more higher than that of eluent A, are passed through in sequence. In addition to such a method utilizing a pH gradient, a method for quickly separating the hemoglobin A0 fraction using an eluent containing multiple salt species has also been reported (Patent Document 4).
[0006] Specifically, this method is characterized in that eluent A used for eluting hemoglobin components eluted before hemoglobin A contains both a chaotropic salt and two salts having acid dissociation constants within a specific range. While such eluent A improves the separation ability of hemoglobin components eluted before hemoglobin A and shortens the analysis time, separation of hemoglobin components eluted after hemoglobin A depends on a pH gradient, as in Patent Document 3.
[0007] As described above, while salt species effective for separating hemoglobin components eluted before hemoglobin A0 have been found, little research has been done on salt species effective for separating hemoglobin components eluted after hemoglobin A0. While it has been shown that a pH gradient of the eluent or the addition of an ion-pair reagent is effective for separating hemoglobin components eluted after hemoglobin A0, the other salt species contained in the eluent have, in most cases, been selected randomly. For example, Patent Document 5 discloses a separation method using a phosphate buffer solution, but its effectiveness has not been thoroughly investigated, and the effects of other salt species on separation have not been systematically understood.
[0008] Japanese Patent Publication No. 2000-055899 Japanese Patent No. 5322736 Japanese Patent No. 4420539 Japanese Patent No. 2014-095638 U.S. Patent No. 04810391
[0009] A. M. Hyde, S. L. Zultanski, J. H. Waldman, Y. -L. Zhong, M. Shevlin, F. Peng, Org. Proess Res. Dev. 2017, 21, 1355.
[0010] The present invention provides an eluent and a method therefor that improve the resolution of components eluted at A0 and beyond in hemoglobin analysis by cation exchange chromatography.
[0011] The present inventors have conducted extensive research into the elution of the hemoglobin A0 component and the eluent used after hemoglobin A0, and have found that the addition of a kosmotropic salt is effective in separating the components eluted after hemoglobin A0.
[0012] Kosmotropic salts are salts that increase the stability of water-water interactions. The strength of kosmotropic properties is generally expressed by the Hofmeister series. This series was defined based on the minimum salt concentration required for salting out after examining various salts. Among anions, salts with a salting-out effect greater than that of chloride anion are considered kosmotropic, while those with a salting-in effect are considered chaotropic. Salt species on the Hofmeister series are also related to various phenomena influenced by similar interactions. For example, the addition of these salt species is known to affect elution behavior in chromatography. However, although the importance of the Hofmeister series has long been recognized, little systematic research has been conducted on salts other than typical species, and only recently has the strength of the salting-out effect been reexamined (Non-Patent Document 1).
[0013] On the other hand, in the HPLC analysis of hemoglobin, although the effectiveness of representative chaotropic salts has been partially demonstrated, the effects of other salt species have still been overlooked. In particular, in the difficult separation of hemoglobin A0 from abnormal hemoglobin E and hemoglobin A2, attention has been paid only to methods using the effects based on principles other than the Hofmeister series, such as pH gradients and ion-pair reagents, and the effects of salt species with buffering properties and salt species used to control elution power have been ignored.
[0014] In response to this, the present inventors have investigated the influence of salt species in the Hofmeister series on separation. Specifically, they prepared an eluent at the same pH with salt species that are in the Hofmeister series or have a structure similar thereto, among salt species that have been used as buffers, and analyzed a sample containing abnormal hemoglobin E to examine in detail the separation pattern from A0. As a result, they found that the ability to separate the A0 component from E was improved by adding a kosmotropic salt, which exhibits properties opposite to those of chaotropic salts in the Hofmeister series, to the eluent, leading to the completion of the present invention.
[0015] The present invention is described in detail below. [1] An eluent used in the analysis of hemoglobin mixtures using cation exchange chromatography for analyzing hemoglobin components eluted after the hemoglobin A0 component, the eluent being used when separating and analyzing at least one of abnormal hemoglobins E, D, S, and C, or hemoglobin A2, from the hemoglobin A0 component, and containing at least one selected from the group consisting of kosmotropic salts in the Hofmeister series or salt species having a similar structure, such as carboxylic acids, hydrochloric acid, and sulfuric acid. [2] The eluent according to [1], wherein the kosmotropic salt contains at least one selected from the group consisting of acetic acid, succinic acid, and hydroxycarboxylic acids. [3] The eluent according to any one of [1] and [2], wherein the kosmotropic salt is citric acid. [4] The eluent according to any one of [1] to [3], wherein the kosmotropic salt is passed through when separating and analyzing the hemoglobin A0 and hemoglobin A2, which are carboxylic acids. [5] The eluent according to [4], wherein the kosmotropic salt is at least one selected from malonic acid, fumaric acid, and a hydroxycarboxylic acid. [6] The eluent according to any one of [4] to [5], wherein the kosmotropic salt is citric acid. [7] A method using the eluent according to any one of [1] to [6], wherein the eluent is used to separate and analyze at least one of abnormal hemoglobin E, D, S, C, and hemoglobin A2 from the hemoglobin A0 component. [8] A method using the eluent according to any one of [1] to [6] above, wherein in addition to the eluent according to any one of [1] to [6] above that is passed when separating and analyzing hemoglobin A0 and abnormal hemoglobin E or A2, at least one eluent having a weaker elution power than the eluent is passed to separate and elute hemoglobin components that are eluted before the A0 component, and after separating and eluting either or both of hemoglobin F and hemoglobin A1c, the eluent according to any one of [1] to [6] above is passed to separate and elute hemoglobin A0 and abnormal hemoglobin E or A2.
[0016] The present invention provides an eluent that improves the resolution of the A0 component in hemoglobin analysis by cation exchange chromatography. Specifically, the present invention provides an eluent that enables efficient separation and analysis of hemoglobin A0 from abnormal hemoglobin E or hemoglobin A2.
[0017] FIG. 1 shows a chromatogram in Comparative Example 1. FIG. 2 shows a chromatogram in Example 1. FIG. 3 shows a chromatogram in Example 3. FIG. 4 shows a chromatogram in Example 5. FIG. 6 shows a chromatogram in Example 7. FIG. 8 shows a chromatogram in Example 9. FIG. 10 shows a chromatogram in Example 11. FIG. 12 shows a chromatogram in Example 13. FIG. 14 shows a chromatogram in Example 15. FIG. 16 shows a chromatogram in Example 17. FIG. 18 shows a chromatogram in Example 19. FIG. 20 shows a chromatogram in Example 21. FIG. 2 shows a chromatogram in Example 21.
[0018] The present invention will be described in detail below. However, the present invention can be embodied in various forms and is not limited to the following embodiments and examples.
[0019] The present invention relates to an eluent containing a kosmotropic salt of acetate or higher anion, which is used to separate hemoglobin E, which is eluted after A0, in cation exchange chromatography using a column packed with a separating agent having cation exchange groups.
[0020] In this case, kosmotropic salts of acetate or higher anions or salt species having a similar structure include the following: Organic acids include carboxylic acids such as monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, and hydroxycarboxylic acids. Inorganic acids include sulfuric acid and hydrochloric acid. Monocarboxylic acids include acetic acid and propionic acid. Dicarboxylic acids include succinic acid, malonic acid, fumaric acid, maleic acid, and phthalic acid. Tricarboxylic acids include tricarballylic acid. Hydroxycarboxylic acids include malic acid, tartaric acid, citric acid, isocitric acid, and lactic acid.
[0021] Preferably, carboxylic acids are used, more preferably acetic acid, succinic acid, or hydroxycarboxylic acids, and even more preferably hydroxycarboxylic acids are used as the kosmotropic salt. Citric acid is particularly desirable. Furthermore, carboxylic acids or hydrochloric acid can be used to separate hemoglobin A0 and hemoglobin A2, which is more difficult than separating hemoglobin A0 and abnormal hemoglobin E. Among these, dicarboxylic acids such as malonic acid or fumaric acid and hydroxycarboxylic acids are more preferred. Even more preferred is citric acid. The counter cations of these anionic kosmotropic salts may be well-known ones, such as sodium salts and potassium salts.
[0022] The eluent may contain at least one kosmotropic salt stronger than the chloride anion, and may contain multiple kosmotropic salts. The kosmotropic salt may be used as a buffer, or may be added as an additive to a buffer solution containing a buffer other than the kosmotropic salt. Examples of buffers other than the kosmotropic salt include organic acids such as amino acids, amines, imidazole, pyridine, tris(hydroxymethyl)aminomethane, glycylglycine, and pyrophosphoric acid. Examples of inorganic acids include phosphoric acid and carbonic acid. Examples of amino acids include aspartic acid, asparagine, and glycine. Examples of amines include ethylenediamine and triethanolamine.
[0023] In addition to the above buffers, Good's buffers can also be used. Examples of Good's buffers include 2-(N-morpholino)ethanesulfonic acid (MES), N-2-hydroxyethylpiperazine-N'-ethanesulfonic acid (HEPES), bis(2-hydroxyethyl)iminotris-(hydroxymethyl)methane (Bistris), Tris, ADA, PIPES, Bistrispropan E, ACES, MOPS, BES, TES, HEPES, HEPPS, Tricin E, Bicin E, glycylglycine, TAPS, and CAPS. When the pH of the eluent used is outside the buffer range of the added kosmotropic salt, it is particularly desirable to combine a kosmotropic salt or other buffer having a buffer range within the pH range of the eluent used.
[0024] The eluent may contain various additives in addition to the kosmotropic salt and other buffer salts. For example, a chaotropic salt, which exhibits properties opposite to those of the kosmotropic salt, may be added. Chaotropic salts can sometimes improve the separation accuracy of components eluted before A0. Therefore, when simultaneously analyzing components eluted before A0 and components eluted after A0, the separation of hemoglobins can be adjusted by adjusting the concentrations of the kosmotropic salt and the chaotropic salt. Preferred chaotropic salts include thiocyanate ions, iodide ions, perchlorate ions, nitrate ions, and bromide ions. Iodide ions, nitrate ions, thiocyanate ions, and perchlorate ions are more preferred. These chaotropic salts may be used alone or in combination.
[0025] A pH adjuster may be added when adjusting the pH of the eluent. Known acids and bases may be used as pH adjusters. Examples of acids include hydrochloric acid, phosphoric acid, nitric acid, and sulfuric acid, and examples of bases include sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, and calcium hydroxide. The concentrations of these acids and bases are not limited and can be added appropriately depending on the target pH of the eluent. Water-soluble organic solvents can also be added depending on the properties of the packing material. Examples of water-soluble organic solvents include methanol, ethanol, acetonitrile, and acetone, and they may be added in amounts that do not cause precipitation of various salts added to the eluent. The eluent may also contain additives such as chelating agents such as EDTA, antioxidants such as glutathione, and sodium azide to improve separation ability.
[0026] The pH range of the eluent containing the above components is not limited. As long as it is within the range commonly used for hemoglobin analysis, the kosmotropic salt will effectively improve separation ability beyond A0. Specifically, the pH range is preferably 4.0 to 8.0, more preferably 5.0 to 7.0. The effect of the kosmotropic salt itself is greatest near the isoelectric point of hemoglobin (pH 6.0 to 8.0), but hemoglobin retention by ion exchange groups is also necessary. Separation ability can also be improved by combining it with known techniques. For example, applying a pH gradient such as that described in Patent Document 3 to an eluent containing a kosmotropic salt can further improve separation performance. The concentration of the kosmotropic salt varies depending on the retention power of the packing material used. When used as a buffer, the concentration should be within a range that provides buffering effect, i.e., 0.1 to 1000 mM, preferably 1 to 500 mM. When used as an additive, the concentration should be 0.1 to 1000 mM, preferably 10 to 100 mM.
[0027] The concentration of the buffer other than the kosmotropic salt may be within a range that provides a buffering effect, such as 0.1 to 1000 mM, and preferably 1 to 500 mM. The concentration of the chaotropic salt may be within a range that provides a known effect of improving separation ability. That is, 0.1 mM to 3000 mM is preferred, 1 mM to 1000 mM is more preferred, and 10 mM to 500 mM is particularly preferred. This is because, if the concentration is lower than 0.1 mM, the separation effect decreases and measurement accuracy deteriorates, and if the concentration is higher than 3000 mM, the separation effect of hemoglobins does not improve any further.
[0028] In the analysis of a hemoglobin mixture using the eluent, not only the three hemoglobin components A0 and A2 or E can be analyzed, but also abnormal hemoglobins E, D, S, and C can be separated. In this case, a gradient using multiple eluents may be used, and either a step gradient or a linear gradient may be used. For example, after separating hemoglobin A0 and abnormal hemoglobin E or A2, one or more eluents having a higher elution power than the eluent may be used to improve the peak shape.
[0029] In particular, since there is a large difference in retention strength between hemoglobins A0, A2, and abnormal hemoglobin E and the abnormal hemoglobins D, S, and C that are eluted later, it is desirable to combine an eluent with a high elution strength in addition to the above-mentioned eluent for highly accurate analysis. In addition, since the residual components with high retention strength in the column significantly impair the column durability, it is desirable to use an eluent with an even higher elution strength in addition to the above-mentioned eluent with high elution strength. When three or more eluents are used, eluents prepared for each eluent may be used, or they may be prepared in-situ by gradient operation in the analyzer.
[0030] In the analysis of a hemoglobin mixture using the eluent, in addition to the eluent containing the kosmotropic salt, an eluent having a weaker elution power than the eluent containing the kosmotropic salt may be used to analyze hemoglobin components eluted before hemoglobin A0. One or more eluents having a weaker elution power may be used. The use of an eluent having a weaker elution power allows the separation of components eluted before A0, and in particular allows the analysis of hemoglobin F and hemoglobin A1c.
[0031] The high-elution power eluent and the low-elution power eluent used in addition to the eluent containing a kosmotropic salt are not limited in terms of their components, and known buffers can be used. They may contain the same components as the eluent containing a kosmotropic salt, or different components, or may not contain a kosmotropic salt. The elution power can be adjusted by changing the salt concentration or pH, but there are no limitations on the range. However, the high-elution power eluent used after the eluent containing a kosmotropic salt is preferably strong enough to sufficiently elute hemoglobin, which has high retention. In particular, when eluting components after abnormal hemoglobin S, it is desirable to use an eluent with a pH of 6.0 to 8.0, which is near the isoelectric point of hemoglobin. The low-elution power eluent preferably has a pH of 4.0 to 6.0 in order to separate components eluted before A0.
[0032] A known technique may be used to improve the degree of separation between these components, for example, by passing an eluent containing a kosmotropic salt through the column, followed by another eluent having a stronger elution power, and then passing an eluent having a weaker elution power than the eluent containing a kosmotropic salt through the column, thereby improving the degree of separation between hemoglobin peaks.
[0033] The liquid chromatography apparatus used for separation using the eluent of the present invention is not particularly limited, and may be a known apparatus. For example, an apparatus comprising a liquid delivery pump, a sample injection device, a column, a column oven, a detector, etc. may be used. In addition, an accessory device such as an eluent degasser may be appropriately attached.
[0034] In cation exchange chromatography using the eluent of the present invention, a column packed with a separating agent having at least one type of cation exchange group is used. For example, a separating agent can be prepared by using polymer particles as a base and introducing cation exchange groups onto the surface. There are no particular restrictions on the cation exchange groups introduced onto the surface, but known groups such as carboxyl groups, sulfo groups, and phosphate groups can be used. Of these, sulfo groups and carboxyl groups are preferred. There are no particular restrictions on the size of the column packed with the separating agent, and an appropriate size can be selected depending on the separation conditions. There are also no particular restrictions on the column material, but known metals such as stainless steel, glass, and resins such as PEEK can be used.
[0035] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
[0036] (Examples 1 to 11, Comparative Example 1) In Examples 1 to 11 and Comparative Example 1, a column prepared as follows was used. This column used a packing material suitable for separating hemoglobin A0, hemoglobin A2, and abnormal hemoglobin E, as disclosed in JP 2018-17560 A. In studies using this column, separation of hemoglobin A0 and abnormal hemoglobin E was investigated using an eluent prepared from a kosmotropic salt of acetic acid or higher in the Hofmeister series, or a salt species having a similar structure. The column packing material was prepared as follows.
[0037] A mixed solution of 350 g of glycidyl methacrylate, 70 g of ethylene glycol dimethacrylate, 30 g of methyl methacrylate, and 10 g of t-butyl perpivalate was stirred in an aqueous solution of 40 g of sodium sulfate and 200 g of polyvinyl alcohol, and a crosslinking polymerization reaction was carried out at a reaction temperature of 60°C for 12 hours to obtain non-porous crosslinked polymer particles with a particle diameter of 3.2 μm.
[0038] 20 g of these crosslinked polymer particles and 20 g of 1,4-cyclohexanedimethanol were dispersed in 200 g of 1,4-dioxane, and 1 mL of boron trifluoride diethyl ether was added, followed by a reaction at 70°C for 16 hours. After the reaction, the gel was washed with 1,4-dioxane and water, and then air-dried to a suction-dried state. 15 g of the suction-dried gel was dispersed in a 42% aqueous sodium hydroxide solution, and allyl glycidyl ether was added dropwise while maintaining the liquid temperature at 40°C. The resulting polymer particles were washed again with water, dispersed in an aqueous sodium sulfite solution, and oxygen gas was blown into the solution, allowing the reaction to proceed for 16 hours.
[0039] The resulting liquid chromatography packing material was packed into a column with an inner diameter of 4.6 mm and a length of 0.8 cm to prepare a column for hemoglobin measurement. A blood sample containing abnormal hemoglobin E was measured under the following conditions: Flow rate: 2.0 mL / min, Monitor wavelength: 415 nm, Step gradient: Eluent A: Buffer solution shown in Table 1 (0-4.0 min), Eluent B: Salt concentration three times that of the buffer solution shown in Table 1 (4.0-5.0 min). The two eluents used are as shown in Table 1 below. Only eluent A was used to separate the hemoglobin components, while eluent B was prepared with a salt concentration three times that of eluent A and was used for column washing. In the comparative example and each example, the salt concentration of eluent A was determined so that the retention time of hemoglobin A0 was constant.
[0040]
[0041] In Table 1 above, Comparative Example 1 used an eluent prepared with perchloric acid, a strong chaotropic salt outside the scope of the present invention. On the other hand, Examples 1 to 10 used kosmotropic salts. In Comparative Example 1, as shown in FIG. 1 , separation of hemoglobin A0 and abnormal hemoglobin E was insufficient. Specifically, when an eluent prepared solely with a strong chaotropic salt such as perchloric acid was used as in Comparative Example 1, the components after A0 were broadened and the separation ability was extremely low. On the other hand, in Examples 1 to 10, in which eluents prepared with various kosmotropic salts were used, good separation of hemoglobin A0 and abnormal hemoglobin E was achieved, as shown in FIGS. 2 to 11 .
[0042] In Example 1, hemoglobin A0 and abnormal hemoglobin E were separated better than in Comparative Example 1 using sulfuric acid. In the case of acetic acid, a monocarboxylic acid in Example 2, the peaks were widely separated and the peak shapes were good. Dicarboxylic acids in Examples 3 to 6 also showed good separation characteristics. Among these, when succinic acid was used as in Example 4, the retention time of hemoglobin A0 remained unchanged, but the difference in retention time of hemoglobin E became large. The difference in retention time between hemoglobin A0 and abnormal hemoglobin E became largest with hydroxycarboxylic acids as in Examples 7 to 9. When hydrochloric acid was used as in Example 10, they were also separated without any problems.
[0043] Furthermore, when the kosmotropic salt used was a carboxylic acid or hydrochloric acid as in Examples 2 to 10, in addition to the separation of hemoglobin A0 and abnormal hemoglobin E, hemoglobin A2 was detected between these peaks. Among the dicarboxylic acids in Examples 2 to 6, when malonic acid and fumaric acid were used, the ability to separate hemoglobin A0 and hemoglobin A2 was high. On the other hand, when hydroxycarboxylic acids such as those in Examples 7 to 9 were used, hemoglobin A0 and hemoglobin A2 could all be efficiently separated. In particular, when citric acid was used in Example 9, the difference in retention time between hemoglobin A0 and A2 was the largest among Examples 2 to 10.
[0044] When hydrochloric acid was used in Example 10, the separation performance was not as high as that of other carboxylic acids, but unlike sulfuric acid, which is also an inorganic salt, hemoglobin A2 could be separated. As described above, hemoglobin A0 and abnormal hemoglobin E or hemoglobin A2 could be separated using kosmotropic salts of acetic acid or higher in the Hofmeister series or salt species having a similar structure. As shown in the investigation of dicarboxylic acids with similar structures, although the optimal solvent may differ depending on the hemoglobin species, it was shown that kosmotropic salts are effective in separating hemoglobin components eluted after hemoglobin A0.
[0045] Furthermore, the eluent is effective if it contains one or more of these kosmotropic salts. As in Example 11, even in an eluent containing perchloric acid, a strong chaotropic salt that is unsuitable for use in separating hemoglobin A0 and subsequent components, hemoglobin A2 and abnormal hemoglobin E could be separated from hemoglobin A0 by adding citric acid.
[0046] Examples 12 to 16 In Examples 12 to 16, a column was used in which a packing material with poorer separation performance for hemoglobin A0, A2, and abnormal hemoglobin E was used compared to the packing material used in Examples 1 to 11. Specifically, hemoglobin was separated using a highly hydrophilic Tosoh TSKgel SP-NPR (inner diameter 4.6 mm, length 3.5 cm). Blood containing abnormal hemoglobin E was used as the measurement sample. In this study, in addition to separating hemoglobin A0 and E, separation of hemoglobin F, a component that elutes before hemoglobin A0, was also performed. Flow rate: 1.5 mL / min Monitor wavelength: 415 nm Step gradient: Eluent A: Phosphate buffer solution (50 mM, pH 6.0) (0-0.5 min) Eluent B: Buffer solution shown in Table 2 (0.5-3.0 min) Eluent C: Phosphate buffer solution (200 mM, pH 6.0) (3.0-5.0 min) The eluent B solution used is as shown in Table 2 below. In this study, hemoglobin F was separated using eluent A, hemoglobin A0 and hemoglobin E were separated using eluent B, and eluent C was used as a cleaning solution. In this study, eluents containing succinic acid or hydroxycarboxylic acids were investigated, for which it was difficult to observe a difference in effectiveness when using packing materials suitable for separating hemoglobin A0 and abnormal hemoglobin E in the above examples. In each example, the salt concentration of eluent B was determined so that the retention time of hemoglobin A0 was constant.
[0047]
[0048] In Examples 12 to 14, the same pH conditions were used for eluent A, which is used to separate components eluted before A0, and eluent B, which is used to elute components eluted after A0, as known in Patent Document 2 to be detrimental to the separation of components A0 and beyond (Table 2). In all cases in Examples 12 to 14, hemoglobin A0 and abnormal hemoglobin E were successfully separated. In this case, hydroxycarboxylic acids such as tartaric acid and citric acid demonstrated better separation than dicarboxylic acid succinic acid. Furthermore, in Example 13, improved resolution between A0 and E was achieved despite the use of an eluent with a pH of 6.0, which is outside the buffer range of tartaric acid (pKa 4.8). This indicates that these kosmotropic salts not only stabilize the chromatographic measurement results as buffers, but also significantly contribute to hemoglobin separation.
[0049] In Examples 15 and 16, the pH of eluent B, which used citric acid as the salt, was investigated. As a result, when eluent B with a pH of 6.5, which is 0.5 higher than eluent A, was used, separation of hemoglobin A0 and abnormal hemoglobin E was extremely good. On the other hand, even when eluent B with a pH of 5.5, which is 0.5 lower than eluent A, was used, the separation performance of hemoglobin A0 and abnormal hemoglobin E was high, and the addition of hydroxycarboxylic acids was found to have a special effect of improving the separation ability. These results demonstrate that the use of a kosmotropic salt appropriate for the separation of hemoglobin A0 and abnormal hemoglobin E is effective, even when packing materials with different properties are used.
[0050] Examples 17-19 In Examples 17-19, the column used in Examples 12-16 was used. Cantabery Control Level 2 was used as the measurement sample. This sample contained abnormal hemoglobin S. Flow rate: 1.5 mL / min. Monitor wavelength: 415 nm. Step gradient: Eluent A: phosphate buffer (50 mM, pH 6.0) (0-0.5 min). Eluent B: buffer listed in Table 3 (0.5-3.0 min). Eluent C: phosphate buffer (200 mM, pH 6.0) (3.0-5.0 min). The eluent B used is shown in Table 3 below. In this study, eluent A was used to separate hemoglobin F, eluent B was used to separate hemoglobin A0 and hemoglobin A2, and eluent C was used as a cleaning solution. In each comparative example and example, the salt concentration of eluent B was determined so that the retention time of hemoglobin A0 was constant.
[0051]
[0052] Even when a packing material suitable for separating hemoglobin A0 and hemoglobin A2 was not used, these peaks could be separated efficiently when citric acid was used as in Example 17. Separation was also possible without problems when a mixture of citric acid and phosphoric acid was used as in Example 18. Furthermore, hemoglobin A0 and hemoglobin A2 could be separated by adding citric acid, a hydroxycarboxylic acid, even when a strong chaotropic salt such as perchloric acid was contained as in Example 19.
[0053] (Examples 20 and 21) In Examples 20 and 21, it was confirmed that the use of this eluent system allowed separation of abnormal hemoglobin D and C from hemoglobin A0. Specifically, when a sample containing abnormal hemoglobin D (Example 20) and a sample containing abnormal hemoglobin C (Example 21) were measured using the conditions of Example 13, each abnormal hemoglobin was successfully separated (FIG. 21: Example 20, FIG. 22: Example 21).
Claims
1. An eluent used in the analysis of hemoglobin mixtures using cation exchange chromatography for the analysis of hemoglobin components eluted after the hemoglobin A0 component, said eluent being passed when separating and analyzing at least one of abnormal hemoglobins E, D, S, C and hemoglobin A2 from the hemoglobin A0 component, and containing at least one selected from the group consisting of carboxylic acids, hydrochloric acid and sulfuric acid, which are cosmotropic salts in the Hofmeister series or salt species having a similar structure thereto.
2. The eluent according to claim 1, wherein the cosmotropic salt is at least one selected from the group consisting of acetic acid, succinic acid, and hydroxycarboxylic acids.
3. The eluent according to any one of claims 1 to 2, wherein the cosmotropic salt is citric acid.
4. An eluent according to any one of claims 1 to 3, wherein the cosmotropic salt is a carboxylic acid and is passed through when separating and analyzing the hemoglobin A0 and A2.
5. The eluent according to claim 4, wherein the cosmotropic salt is at least one selected from the group consisting of malonic acid, fumaric acid, and hydroxycarboxylic acid.
6. The eluent according to any one of claims 4 to 5, wherein the cosmotropic salt is citric acid.
7. A method for separating and analyzing at least one of abnormal hemoglobin E, D, S, C and hemoglobin A2 from the hemoglobin A0 component, using an eluent according to any one of claims 1 to 6.
8. A method using an eluent according to any one of claims 1 to 6, comprising, in addition to the eluent according to any one of claims 1 to 6 used in separating and analyzing hemoglobin A0 and abnormal hemoglobin E or A2, passing at least one eluent having a weaker elution power than the eluent, thereby separating and eluting a hemoglobin component which is eluted before the A0 component, and separating and eluting either or both of hemoglobin F and hemoglobin A1c, by passing the eluent according to any one of claims 1 to 6.
Citation Information
Patent Citations
Measuring method for hemoglobins
JP2000055899A
Method for separating hemoglobin A2
JP4420539B2
Methods for analyzing hemoglobins and proteins
JP5322736B2
Separation of hemoglobin A2 from hemoglobin mixture
US4810391A
Method for separating hemoglobin a2
JP2001159625A
